Overview
Sermorelin is the shortest fully functional fragment of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids. It was FDA-approved in 1997 as Geref for diagnosing and treating growth hormone deficiency in children, though it was discontinued commercially in 2008. It remains one of the most well-studied GH-releasing peptides with established clinical safety data.
Mechanism of action
Sermorelin binds to the GHRH receptor on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone. Unlike exogenous GH administration, sermorelin preserves the hypothalamic-pituitary feedback loop, maintaining physiological GH regulation. It stimulates all five somatotroph cell subtypes.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| anti-aging / GH optimization | subcutaneous | 200–500 mcg | daily at bedtime | Inject before sleep to synergize with natural nocturnal GH pulse. 3-6 month cycles recommended. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Extensive clinical trial data from FDA approval process. Studies demonstrate significant increases in GH and IGF-1 levels, improved body composition (reduced fat mass, increased lean mass), improved sleep quality (increased slow-wave sleep), and improved skin elasticity. The Rudman 1990 NEJM study on GH in aging and subsequent sermorelin studies established the foundation for anti-aging peptide use.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Sermorelin for synergistic effects.
Legal status
Previously FDA-approved (Geref, 1997). Discontinued commercially in 2008 but still available through compounding pharmacies. Under reclassification review.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings. Supplier listings will be available if FDA reclassification is formalized.